Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Humana ABLTS:0RF7 -2.27%53 3-Year EBITDA Growth Rate is 5.90% as of Jun. 2026, which is 51% below its 10-year median of 12.00. GuruFocus rates LTS:0RF7 with a GF Score™ of 53/100 and a GF Value™ of kr37.19 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Humana AB ranks worse than 58.94% on this metric.
During the past 12 months, Humana AB's average EBITDA Per Share Growth Rate was -4.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 6.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Humana AB was 31.10% per year. The lowest was 4.20% per year. And the median was 12.00% per year.
Humana AB (LTS:0RF7) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Humana AB 3-Year EBITDA Growth Rate Related Terms
LTS:0RF7 vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Humana AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Humana AB 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Humana AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Humana AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.90% mean?
Humana AB (LTS:0RF7) has a 3-Year EBITDA Growth Rate of 5.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Humana AB and its competitors. This is 51% below median its historical median of 12.00. Over the past decade, Humana AB's 3-Year EBITDA Growth Rate has ranged from 4.20 to 31.10. According to the industry distribution chart, Humana AB ranks #310 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 58.9%.
Is Humana AB's 3-Year EBITDA Growth Rate too high?
Humana AB's current 3-Year EBITDA Growth Rate of 5.90% is 51% below median its 10-year median of 12.00. Over the past 10 years, this metric has ranged from a low of 4.20 to a high of 31.10. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.05. Humana AB's value of 5.90% is 41.3% below this industry median. Based on the distribution chart, Humana AB ranks #310 out of 526 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Humana AB has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Humana AB's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Humana AB ranks #310 out of 526 companies for 3-Year EBITDA Growth Rate. This places Humana AB in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.05. Humana AB's value of 5.90% is 41.3% below this benchmark. Historically, Humana AB's own 3-Year EBITDA Growth Rate has ranged from 4.20 to 31.10 over the past decade. While the company's 10-year median is 12.00 vs. the industry median of 10.05, Humana AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Humana AB's current 3-Year EBITDA Growth Rate of 5.90% is 41.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Humana AB and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Humana AB's current 3-Year EBITDA Growth Rate is 5.90%, which is 51% below median its own 10-year median of 12.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humana AB stock overvalued right now?
Based on GuruFocus' analysis, Humana AB (LTS:0RF7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr37.19, compared to a current price of kr71.05 — trading 91% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.90%, which is 51% below median its 10-year median of 12.00 and 41.3% below the Healthcare Providers & Services industry median of 10.05. Humana AB's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Humana AB (LTS:0RF7), the current 3-Year EBITDA Growth Rate is 5.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Humana AB (LTS:0RF7) Overvalued in 2026?
Based on GuruFocus' analysis, Humana AB stock appears to be overvalued.
The current stock price of kr71.05 is trading 91% above its estimated GF Value™ of kr37.19.
GuruFocus considers Humana AB to be Significantly Overvalued.
Key valuation signals for LTS:0RF7:
3-Year EBITDA Growth Rate: 5.90% (51% below median its 10-year median of 12.00)
GF Value™: kr37.19 vs. price of kr71.05 (91% above fair value)
Industry Position: 41.3% below the Healthcare Providers & Services median (#310 of 526)
No single metric tells the full story. See the LTS:0RF7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Humana AB is a provider of private care services in the Nordic region. The company offers services including individual and family care, personal assistance, elderly care and housing with special services. Geographically, the company operates in Sweden, Norway, Finland, Denmark, and others. It derives maximum revenue from Sweden.
53GF Score
Get the complete analysis for LTS:0RF7
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RF7 has been successfully added to your 
